Limits...
Lipid disturbances in psoriasis: an update.

Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC - Mediators Inflamm. (2010)

Bottom Line: Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse.In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications.Dyslipidemia is one of comorbidities in psoriatic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, ul. Radziwillowska 13, 20-080 Lublin, Poland.

ABSTRACT
Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

Show MeSH

Related in: MedlinePlus

Psoriasis and cardiovascular abnormalities. This figure is a modified one (after permission) from [19].
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2914266&req=5

fig4: Psoriasis and cardiovascular abnormalities. This figure is a modified one (after permission) from [19].

Mentions: There was a strong association observed between arterial stiffness, which is endothelial dysfunction marker, and the risk of cardiovascular events. Pulse wave velocity (PWV) is the gold standard measurement of arterial stiffness and in the patients with psoriasis and psoriatic arthritis an increased femoral-carotid PWV was observed [127, 143]. There were also functional and structural changes in the myocardium, changes in electrocardiographic activity, such as increased P wave dispersion, and structural changes in coronary vessels in psoriatic patients (Figure 4) [7, 19, 144].


Lipid disturbances in psoriasis: an update.

Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC - Mediators Inflamm. (2010)

Psoriasis and cardiovascular abnormalities. This figure is a modified one (after permission) from [19].
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2914266&req=5

fig4: Psoriasis and cardiovascular abnormalities. This figure is a modified one (after permission) from [19].
Mentions: There was a strong association observed between arterial stiffness, which is endothelial dysfunction marker, and the risk of cardiovascular events. Pulse wave velocity (PWV) is the gold standard measurement of arterial stiffness and in the patients with psoriasis and psoriatic arthritis an increased femoral-carotid PWV was observed [127, 143]. There were also functional and structural changes in the myocardium, changes in electrocardiographic activity, such as increased P wave dispersion, and structural changes in coronary vessels in psoriatic patients (Figure 4) [7, 19, 144].

Bottom Line: Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse.In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications.Dyslipidemia is one of comorbidities in psoriatic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, ul. Radziwillowska 13, 20-080 Lublin, Poland.

ABSTRACT
Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

Show MeSH
Related in: MedlinePlus